BCL2 and neoplasm: Moving forward, these studies provide a clear path for using our knowledge of lineage-encoded BCL-2 protein dependencies3, alongside functional assays like dynamic BH3 profiling, to select BH3 mimetic agents to administer alongside targeted therapies, then to use knowledge of the kinetics of targeted therapy-induced apoptotic priming to define intermittent dosing regimens that drive efficient tumor cell death while minimizing toxicities.